Research Paper Volume 16, Issue 9 pp 7647—7667
GJB3: a comprehensive biomarker in pan-cancer prognosis and immunotherapy prediction
Figure 5. With different cancers, GJB3 expression varies depending on clinical characteristics. (A–H) Analysis of the relationship between GJB3 level and clinicopathological stage in COAD, KIRC, ESCA, BRCA, THCA, READ, LUAD, and KIRP patients. (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).